Hepatitis C virus receptor expression in normal and diseased liver tissue.

PubWeight™: 2.43‹?› | Rank: Top 2%

🔗 View Article (PMID 18085708)

Published in Hepatology on February 01, 2008

Authors

Gary M Reynolds1, Helen J Harris, Adam Jennings, Ke Hu, Joe Grove, Patricia F Lalor, David H Adams, Peter Balfe, Stefan G Hübscher, Jane A McKeating

Author Affiliations

1: Liver Laboratories, Institute for Biomedical Research, University of Birmingham and University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Articles citing this

Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84

The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 1.69

Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol (2015) 1.67

RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65

CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62

Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54

Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47

Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41

Molecular mechanisms of hepatic apoptosis. Cell Death Dis (2014) 1.21

Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol (2009) 1.19

Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol (2009) 1.14

Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. Virol J (2009) 1.12

Heterogeneous claudin-1 expression in human liver. Hepatology (2013) 1.11

Hepatocyte polarity. Compr Physiol (2013) 1.06

Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol (2009) 1.04

Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03

Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J (2009) 1.01

A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol (2011) 1.00

Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J Hepatol (2013) 0.96

The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog (2010) 0.89

Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol (2013) 0.89

Mechanisms of viral entry: sneaking in the front door. Protoplasma (2010) 0.88

Connections matter--how viruses use cell–cell adhesion components. J Cell Sci (2015) 0.87

Targeting HCV entry for development of therapeutics. Viruses (2010) 0.86

CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84

Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J Virol (2013) 0.84

Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep (2015) 0.84

New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83

CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses (2014) 0.83

Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. J Virol (2015) 0.80

Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. J Virol (2012) 0.79

A role for CD81 and hepatitis C virus in hepatoma mobility. Viruses (2014) 0.78

Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus. PLoS One (2012) 0.78

CD81 promotes both the degradation of transferrin receptor 2 (TfR2) and the Tfr2-mediated maintenance of hepcidin expression. J Biol Chem (2015) 0.77

Active RNA replication of hepatitis C virus downregulates CD81 expression. PLoS One (2013) 0.77

Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein. PLoS One (2016) 0.76

The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76

Implication of tetraspanin-enriched microdomains (TEMs) in hepatitis C virus. Hepatology (2008) 0.75

Claudins in viral infection: from entry to spread. Pflugers Arch (2016) 0.75

Articles by these authors

Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05

Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 5.31

Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84

Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69

CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53

Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10

Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09

Aortic valve surgery after previous coronary artery bypass grafting with functioning internal mammary artery grafts. Ann Thorac Surg (2002) 2.88

Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77

Results and predictors of early and late outcomes of coronary artery bypass graft surgery in octogenarians. J Cardiothorac Vasc Anesth (2007) 2.73

Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65

Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med (2011) 2.47

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45

EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr (2012) 2.41

Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology (2010) 2.37

Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med (2007) 2.32

A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry (2006) 2.28

Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23

Integrated thoracic residency program applicants: the best and the brightest? Ann Thorac Surg (2011) 2.22

Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A (2010) 2.19

Bilateral internal mammary artery grafts, mortality and morbidity: an analysis of 1 526 360 coronary bypass operations. Heart (2013) 2.15

The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology (2002) 2.12

Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07

Management of systolic anterior motion after mitral valve repair: an algorithm. J Thorac Cardiovasc Surg (2012) 2.07

Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05

Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04

Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg (2008) 2.04

Cardiac myxoma: preoperative diagnosis using a multimodal imaging approach and surgical outcome in a large contemporary series. Interact Cardiovasc Thorac Surg (2007) 2.03

An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med (2006) 2.00

CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95

Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92

Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87

Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood (2011) 1.83

Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology (2010) 1.82

Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation (2009) 1.78

A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J (2010) 1.78

Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76

Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg (2008) 1.76

A three-dimensional ring annuloplasty for the treatment of tricuspid regurgitation. Ann Thorac Surg (2006) 1.75

Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71

Organellar dynamics during the cell cycle of Toxoplasma gondii. J Cell Sci (2008) 1.70

Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68

Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67

Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67

Golgi biogenesis in Toxoplasma gondii. Nature (2002) 1.67

The intraoperative "ink test": a novel assessment tool in mitral valve repair. J Thorac Cardiovasc Surg (2007) 1.64

CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62

Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics (2011) 1.62

Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol (2010) 1.61

Incidence, topography, predictors and long-term survival after stroke in patients undergoing coronary artery bypass grafting. Ann Thorac Surg (2008) 1.60

Primary sclerosing cholangitis. Lancet (2013) 1.59

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med (2005) 1.57

Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol (2002) 1.55

Measuring tubulin content in Toxoplasma gondii: a comparison of laser-scanning confocal and wide-field fluorescence microscopy. Proc Natl Acad Sci U S A (2002) 1.55

Inverted left atrial appendage. J Am Coll Cardiol (2009) 1.55

Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54

Predictors and early and late outcomes of dialysis-dependent patients in contemporary cardiac surgery. J Cardiothorac Vasc Anesth (2008) 1.54

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry (2009) 1.53

CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol (2005) 1.49

Recruitment of lymphocytes to the human liver. Immunol Cell Biol (2002) 1.49

Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48

Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47

Tracheostomy is not a risk factor for deep sternal wound infection after cardiac surgery. Ann Thorac Surg (2007) 1.46

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46

Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology (2009) 1.46